Pfizer To Fold CovX Into Bioinnovation Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer acquires privately held California biotherapeutics company focused on preclinical oncology and metabolic research.
You may also be interested in...
Pfizer Clears Out Pipeline: After Oncology Disappointments, Talks Up Diabetes
Pfizer’s latest major pipeline clear-out resulted in losses of Sutent development in a number of cancers and figitumumab in non-small cell lung cancer, among many other discontinuations.
Pfizer Clears Out Pipeline: After Oncology Disappointments, Talks Up Diabetes
Pfizer’s latest major pipeline clear-out resulted in losses of Sutent development in a number of cancers and figitumumab in non-small cell lung cancer, among many other discontinuations.
Pfizer Strengthens Therapeutic Vaccine Position With Coley Purchase
Pharma giant gains control over Coley’s Toll-like receptor patent estate and next-generation vaccine adjuvants with $164 million acquisition.